scholarly journals Neuroprotective Agents in Glaucoma

10.5772/19067 ◽  
2011 ◽  
Author(s):  
Eleni Bagli ◽  
George Kitsos
Keyword(s):  
Neuroprotective Agents

Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson’s Disease

2020 ◽  
Vol 26 (37) ◽  
pp. 4738-4746
Author(s):  
Mohan K. Ghanta ◽  
P. Elango ◽  
Bhaskar L. V. K. S.
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Diagnosis ◽  
Neurodegenerative Disorder ◽  
Therapeutic Strategies ◽  
Neuroprotective Agents ◽  
Striatal Neurons ◽  
The Status ◽  
Advanced Stages ◽  
Dopaminergic Pathways

Parkinson’s disease is a progressive neurodegenerative disorder of dopaminergic striatal neurons in basal ganglia. Treatment of Parkinson’s disease (PD) through dopamine replacement strategies may provide improvement in early stages and this treatment response is related to dopaminergic neuronal mass which decreases in advanced stages. This treatment failure was revealed by many studies and levodopa treatment became ineffective or toxic in chronic stages of PD. Early diagnosis and neuroprotective agents may be a suitable approach for the treatment of PD. The essentials required for early diagnosis are biomarkers. Characterising the striatal neurons, understanding the status of dopaminergic pathways in different PD stages may reveal the effects of the drugs used in the treatment. This review updates on characterisation of striatal neurons, electrophysiology of dopaminergic pathways in PD, biomarkers of PD, approaches for success of neuroprotective agents in clinical trials. The literature was collected from the articles in database of PubMed, MedLine and other available literature resources.

An Overview of Stroke: Mechanism, In vivo Experimental Models Thereof, and Neuroprotective Agents

2020 ◽  
Vol 21 (9) ◽  
pp. 860-877
Author(s):  
Mohd Muazzam Khan ◽  
Badruddeen ◽  
Mohd Mujahid ◽  
Juber Akhtar ◽  
Mohammad Irfan Khan ◽  
...  
Keyword(s):  
Causes Of Death ◽  
Active Form ◽  
Experimental Models ◽  
Global Cerebral Ischemia ◽  
Channel Blockers ◽  
Neuroprotective Agents ◽  
Decisive Action ◽  
Stroke Mechanism ◽  
Injury Outcomes

Background: Stroke is one of the causes of death and disability globally. Brain attack is because of the acute presentation of stroke, which highlights the requirement for decisive action to treat it. Objective: The mechanism and in-vivo experimental models of stroke with various neuroprotective agents are highlighted in this review. Method: The damaging mechanisms may proceed by rapid, nonspecific cell lysis (necrosis) or by the active form of cell death (apoptosis or necroptosis), depending upon the duration and severity and of the ischemic insult. Results: Identification of injury mediators and pathways in a variety of experimental animal models of global cerebral ischemia has directed to explore the target-specific cytoprotective strategies, which are critical to clinical brain injury outcomes. Conclusion: The injury mechanism, available encouraging medicaments thereof, and outcomes of natural and modern medicines for ischemia have been summarized. In spite of available therapeutic agents (thrombolytics, calcium channel blockers, NMDA receptor antagonists and antioxidants), there is a need for an ideal drug for strokes.

scholarly journals Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid

2021 ◽  
Vol 22 (1) ◽  
pp. 403
Author(s):  
Fanni Tóth ◽  
Edina Katalin Cseh ◽  
László Vécsei
Keyword(s):  
Neurodegenerative Diseases ◽  
Lipoic Acid ◽  
Kynurenic Acid ◽  
Biological Activities ◽  
Neuroprotective Effect ◽  
Structural Diversity ◽  
Kynurenine Pathway ◽  
Glutamate Excitotoxicity ◽  
Neuroprotective Agents ◽  
Starting Point

The incidence of neurodegenerative diseases has increased greatly worldwide due to the rise in life expectancy. In spite of notable development in the understanding of these disorders, there has been limited success in the development of neuroprotective agents that can slow the progression of the disease and prevent neuronal death. Some natural products and molecules are very promising neuroprotective agents because of their structural diversity and wide variety of biological activities. In addition to their neuroprotective effect, they are known for their antioxidant, anti-inflammatory and antiapoptotic effects and often serve as a starting point for drug discovery. In this review, the following natural molecules are discussed: firstly, kynurenic acid, the main neuroprotective agent formed via the kynurenine pathway of tryptophan metabolism, as it is known mainly for its role in glutamate excitotoxicity, secondly, the dietary supplement pantethine, that is many sided, well tolerated and safe, and the third molecule, α-lipoic acid is a universal antioxidant. As a conclusion, because of their beneficial properties, these molecules are potential candidates for neuroprotective therapies suitable in managing neurodegenerative diseases.

scholarly journals Phenotypic Discovery of Neuroprotective Agents by Regulation of Tau Proteostasis via Stress‐Responsive Activation of PERK Signaling

2021 ◽  
Author(s):  
Young‐Hee Shin ◽  
Hana Cho ◽  
Bo Young Choi ◽  
Jonghoon Kim ◽  
Jaeyoung Ha ◽  
...  
Keyword(s):  
Neuroprotective Agents

Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment

Neurology ◽  
2003 ◽  
Vol 60 (8) ◽  
pp. 1234-1240 ◽  
Author(s):  
B.M. Ravina ◽  
S.C. Fagan ◽  
R.G. Hart ◽  
C.A. Hovinga ◽  
D.D. Murphy ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Neuroprotective Agents ◽  
Systematic Assessment

scholarly journals Triazolbenzo[d]thiazoles: Efficient synthesis and biological evaluation as neuroprotective agents

2012 ◽  
Vol 22 (18) ◽  
pp. 5976-5978 ◽  
Author(s):  
Belem Avila ◽  
Aaron Roth ◽  
Heather Streets ◽  
Donard S. Dwyer ◽  
Mark J. Kurth
Keyword(s):  
Biological Evaluation ◽  
Neuroprotective Agents ◽  
Efficient Synthesis ◽  
Synthesis And Biological Evaluation

Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: A multimodal analysis

Neuroscience ◽  
2007 ◽  
Vol 144 (4) ◽  
pp. 1293-1304 ◽  
Author(s):  
E. Leonelli ◽  
R. Bianchi ◽  
G. Cavaletti ◽  
D. Caruso ◽  
D. Crippa ◽  
...  
Keyword(s):  
Diabetic Neuropathy ◽  
Neuroprotective Agents ◽  
Multimodal Analysis ◽  
Experimental Diabetic Neuropathy
Sign in / Sign up

Export Citation Format

Share Document